Vertex Pharmaceuticals (Brazil) Today
| VRTX34 Stock | BRL 604.58 7.92 1.29% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Vertex Pharmaceuticals is trading at 604.58 as of the 23rd of December 2024, a 1.29 percent decrease since the beginning of the trading day. The stock's open price was 612.5. Vertex Pharmaceuticals has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 29th of December 2023 and ending today, the 23rd of December 2024. Click here to learn more.
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. VERTEX PHARMDRN operates under Biotechnology classification in Brazil and is traded on Sao Paolo Stock Exchange. The company has 1.03 B outstanding shares. More on Vertex Pharmaceuticals Incorporated
Moving against Vertex Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Vertex Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Vertex Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Vertex Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Reshma Kewalramani |
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Vertex Pharmaceuticals Incorporated (VRTX34) is traded on Sao Paulo Exchange in Brazil and employs 4,800 people. The company currently falls under 'Mega-Cap' category with a current market capitalization of 403.29 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Vertex Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Vertex Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Vertex Pharmaceuticals operates under Healthcare sector and is part of Biotechnology industry. The entity has 1.03 B outstanding shares.
Vertex Pharmaceuticals Incorporated has accumulated about 6.71 B in cash with 2.64 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.46.
Check Vertex Pharmaceuticals Probability Of Bankruptcy
Vertex Pharmaceuticals Risk Profiles
Although Vertex Pharmaceuticals' alpha and beta are two of the key measurements used to evaluate Vertex Pharmaceuticals' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.48 | |||
| Standard Deviation | 2.42 | |||
| Variance | 5.86 | |||
| Risk Adjusted Performance | (0.02) |
Vertex Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Vertex Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Dashboard Now
Portfolio DashboardPortfolio dashboard that provides centralized access to all your investments |
| All Next | Launch Module |
Vertex Pharmaceuticals Corporate Management
Elected by the shareholders, the Vertex Pharmaceuticals' board of directors comprises two types of representatives: Vertex Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vertex. The board's role is to monitor Vertex Pharmaceuticals' management team and ensure that shareholders' interests are well served. Vertex Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vertex Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Young | Independent Director | Profile | |
| Michael Parini | Executive Vice President Chief Legal and Administrative Officer | Profile | |
| Alan Garber | Independent Director | Profile | |
| Mike Tirozzi | SVP Officer | Profile | |
| Damian Esq | Chief VP | Profile | |
| Jeffrey MD | Ex Chairman | Profile |
Other Information on Investing in Vertex Stock
Vertex Pharmaceuticals financial ratios help investors to determine whether Vertex Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Vertex with respect to the benefits of owning Vertex Pharmaceuticals security.